BioWorld: The Daily Biopharmaceutical and Medical Technology …
These cookies are used to enable social media sharing or “like” buttons on our services. They also provide the ability to link your account or engage with our content on or through a social media platform such as Facebook, Twitter or LinkedIn.
BioWorld: The Daily Biopharmaceutical News Source
3 days ago · With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with inhibitors.
NA-931 reduces body weight and improves metabolic profile in
Jul 1, 2024 · Biomed Industries Inc. has presented data on its IGF-1/GLP-1/GIP/GCGR quadruple agonist NA-931 for the treatment of obesity and metabolic disorders. The company has discovered a family of IGF-1 metabolites, known as NA-931, and its analogues NA-932 and NA-933, which are referred to as NA-931 compounds.
No magic with Abbott’s Amulet compared to Watchman
Nov 19, 2024 · Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage occluder system from Boston Scientific Corp.’s market-dominant Watchman device beyond the ability to forego anticoagulants quickly after implantation.
Discovery of AZD-4144, a potent, direct and selective NLPR3 ...
Sep 10, 2024 · Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases; the drug is currently in phase I trials for cardiorenal disease (NCT06491550, NCT06122714).
China - Articles - BioWorld
2 days ago · China's National Medical Products Administration (NMPA) approved Innovent Biologics Inc.’s NDA for Dovbleron (taletrectinib), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for treating adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs.
Epimab licenses BCMA bispecific to startup Vignette in $635M deal
Sep 6, 2024 · In a deal that brings $60 million in cash and equity up front, plus up to $575 million in milestone payments, Shanghai-based Epimab Biotherapeutics Inc. and San Diego-based Vignette Bio Inc. entered a licensing agreement for Epimab’s BCMA-targeting T-cell engager, EMB-06, for autoimmune disease.
TNF-α/OX40L bispecific antibody shows efficacy in models of …
Nov 28, 2023 · Researchers from Seoul National University presented results of preclinical evaluation of a new TNF-α/OX40L bispecific antibody, IMB-101, being developed for the treatment of rheumatoid arthritis (RA).
| BioWorld
May 14, 1992 · Scios Inc. and Nova Pharmaceutical Corp. announced onWednesday that they will merge in an exchange of stockvalued at $180 million. The company, to be called Scios-Nova Inc., will combine Scios'expertise in biotechnology with Nova's strength in smallmolecules, receptor technology and rational drug design, saidRichard Casey, president and chief executive of Scios.
Loxo Oncology’s LY-4066434 demonstrates efficacy in KRAS
Oct 24, 2023 · Researchers from Loxo Oncology at Eli Lilly and Co. recently reported the discovery and preclinical evaluation of a new highly potent and selective pan-KRAS inhibitor, LY-4066434, being developed for the treatment of cancer.